4592.T Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (19 Apr 2024 @ 02:15):

Stats
Today's Volume	583 100
Average Volume	1.70M
Market Cap	29.03B
EPS	¥0 ( 2024-03-17 )
Next earnings date	( ¥0 ) 2024-06-11
Last Dividend	¥0 ( N/A )
Next Dividend	¥0 ( N/A )
P/E	-10.45
ATR14	¥0.683 (0.16%)

Volume Correlation

Long: -0.14 (neutral)

Short: 0.31 (neutral)

Signal:(39.994) Neutral

SanBio Company Limited Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

SanBio Company Limited Correlation - Currency/Commodity

0.15
( neutral )

0.30
( neutral )

-0.54
( weak negative )

0.13
( neutral )

-0.20
( neutral )

0.14
( neutral )

SanBio Company Limited Financials

Annual	2023
Revenue:	¥0
Gross Profit:	¥-14.50M (0.00 %)
EPS:	¥-40.48

Q4	2023
Revenue:	¥0
Gross Profit:	¥-2.39M (0.00 %)
EPS:	¥-11.49

Q3	2023
Revenue:	¥0
Gross Profit:	¥-3.48M (0.00 %)
EPS:	¥-1.460

Q2	2023
Revenue:	¥0
Gross Profit:	¥-4.09M (0.00 %)
EPS:	¥-17.89

Financial Reports:

No articles found.

SanBio Company Limited

SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, spinal cord injury, Parkinson's disease, Alzheimer's disease, and others; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.